QQQ   435.27 (-0.53%)
AAPL   181.42 (-0.66%)
MSFT   407.72 (+0.06%)
META   484.02 (-0.62%)
GOOGL   136.38 (-1.80%)
AMZN   173.16 (-0.22%)
TSLA   202.04 (+1.16%)
NVDA   776.63 (-1.32%)
NIO   5.44 (-6.05%)
AMD   176.54 (-0.82%)
BABA   74.60 (-3.96%)
T   16.96 (+0.77%)
F   12.30 (+2.50%)
MU   89.71 (-2.33%)
CGC   3.36 (-4.82%)
GE   155.62 (+1.06%)
DIS   110.81 (+1.27%)
AMC   5.00 (+3.95%)
PFE   27.06 (+0.59%)
PYPL   60.25 (+0.15%)
XOM   104.37 (+0.33%)
QQQ   435.27 (-0.53%)
AAPL   181.42 (-0.66%)
MSFT   407.72 (+0.06%)
META   484.02 (-0.62%)
GOOGL   136.38 (-1.80%)
AMZN   173.16 (-0.22%)
TSLA   202.04 (+1.16%)
NVDA   776.63 (-1.32%)
NIO   5.44 (-6.05%)
AMD   176.54 (-0.82%)
BABA   74.60 (-3.96%)
T   16.96 (+0.77%)
F   12.30 (+2.50%)
MU   89.71 (-2.33%)
CGC   3.36 (-4.82%)
GE   155.62 (+1.06%)
DIS   110.81 (+1.27%)
AMC   5.00 (+3.95%)
PFE   27.06 (+0.59%)
PYPL   60.25 (+0.15%)
XOM   104.37 (+0.33%)
QQQ   435.27 (-0.53%)
AAPL   181.42 (-0.66%)
MSFT   407.72 (+0.06%)
META   484.02 (-0.62%)
GOOGL   136.38 (-1.80%)
AMZN   173.16 (-0.22%)
TSLA   202.04 (+1.16%)
NVDA   776.63 (-1.32%)
NIO   5.44 (-6.05%)
AMD   176.54 (-0.82%)
BABA   74.60 (-3.96%)
T   16.96 (+0.77%)
F   12.30 (+2.50%)
MU   89.71 (-2.33%)
CGC   3.36 (-4.82%)
GE   155.62 (+1.06%)
DIS   110.81 (+1.27%)
AMC   5.00 (+3.95%)
PFE   27.06 (+0.59%)
PYPL   60.25 (+0.15%)
XOM   104.37 (+0.33%)
QQQ   435.27 (-0.53%)
AAPL   181.42 (-0.66%)
MSFT   407.72 (+0.06%)
META   484.02 (-0.62%)
GOOGL   136.38 (-1.80%)
AMZN   173.16 (-0.22%)
TSLA   202.04 (+1.16%)
NVDA   776.63 (-1.32%)
NIO   5.44 (-6.05%)
AMD   176.54 (-0.82%)
BABA   74.60 (-3.96%)
T   16.96 (+0.77%)
F   12.30 (+2.50%)
MU   89.71 (-2.33%)
CGC   3.36 (-4.82%)
GE   155.62 (+1.06%)
DIS   110.81 (+1.27%)
AMC   5.00 (+3.95%)
PFE   27.06 (+0.59%)
PYPL   60.25 (+0.15%)
XOM   104.37 (+0.33%)

Cytokinetics (CYTK) Competitors

$73.09
-7.90 (-9.75%)
(As of 02/28/2024 ET)

CYTK vs. ELAN, APLS, JAZZ, CERE, VKTX, ITCI, ASND, IONS, ROIV, and BPMC

Should you be buying Cytokinetics stock or one of its competitors? The main competitors of Cytokinetics include Elanco Animal Health (ELAN), Apellis Pharmaceuticals (APLS), Jazz Pharmaceuticals (JAZZ), Cerevel Therapeutics (CERE), Viking Therapeutics (VKTX), Intra-Cellular Therapies (ITCI), Ascendis Pharma A/S (ASND), Ionis Pharmaceuticals (IONS), Roivant Sciences (ROIV), and Blueprint Medicines (BPMC). These companies are all part of the "pharmaceutical preparations" industry.

Cytokinetics vs.

Cytokinetics (NASDAQ:CYTK) and Elanco Animal Health (NYSE:ELAN) are both mid-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, community ranking, analyst recommendations, profitability, dividends, valuation and earnings.

In the previous week, Elanco Animal Health had 9 more articles in the media than Cytokinetics. MarketBeat recorded 30 mentions for Elanco Animal Health and 21 mentions for Cytokinetics. Elanco Animal Health's average media sentiment score of 0.22 beat Cytokinetics' score of 0.13 indicating that Elanco Animal Health is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Cytokinetics
3 Very Positive mention(s)
2 Positive mention(s)
11 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Elanco Animal Health
5 Very Positive mention(s)
6 Positive mention(s)
9 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral

Elanco Animal Health has higher revenue and earnings than Cytokinetics. Cytokinetics is trading at a lower price-to-earnings ratio than Elanco Animal Health, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cytokinetics$94.59M79.53-$388.95M-$5.52-13.90
Elanco Animal Health$4.42B1.81-$78M-$2.50-6.50

Elanco Animal Health has a net margin of -27.87% compared to Cytokinetics' net margin of -6,736.12%. Elanco Animal Health's return on equity of 6.26% beat Cytokinetics' return on equity.

Company Net Margins Return on Equity Return on Assets
Cytokinetics-6,736.12% N/A -61.48%
Elanco Animal Health -27.87%6.26%2.87%

Cytokinetics has a beta of 0.73, meaning that its stock price is 27% less volatile than the S&P 500. Comparatively, Elanco Animal Health has a beta of 1.29, meaning that its stock price is 29% more volatile than the S&P 500.

95.3% of Elanco Animal Health shares are held by institutional investors. 3.8% of Cytokinetics shares are held by company insiders. Comparatively, 0.6% of Elanco Animal Health shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Cytokinetics received 635 more outperform votes than Elanco Animal Health when rated by MarketBeat users. Likewise, 79.03% of users gave Cytokinetics an outperform vote while only 54.17% of users gave Elanco Animal Health an outperform vote.

CompanyUnderperformOutperform
CytokineticsOutperform Votes
765
79.03%
Underperform Votes
203
20.97%
Elanco Animal HealthOutperform Votes
130
54.17%
Underperform Votes
110
45.83%

Cytokinetics currently has a consensus price target of $73.94, indicating a potential downside of 3.37%. Elanco Animal Health has a consensus price target of $16.71, indicating a potential upside of 1.48%. Given Elanco Animal Health's higher probable upside, analysts clearly believe Elanco Animal Health is more favorable than Cytokinetics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cytokinetics
0 Sell rating(s)
2 Hold rating(s)
13 Buy rating(s)
0 Strong Buy rating(s)
2.87
Elanco Animal Health
1 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.57

Summary

Elanco Animal Health beats Cytokinetics on 12 of the 18 factors compared between the two stocks.


Get Cytokinetics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CYTK and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CYTK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CYTK vs. The Competition

MetricCytokineticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$7.52B$6.71B$4.97B$7.45B
Dividend YieldN/A2.80%2.90%3.88%
P/E Ratio-13.907.91184.0313.79
Price / Sales79.53169.693,092.9064.41
Price / CashN/A19.1294.5754.63
Price / Book-67.304.914.534.68
Net Income-$388.95M$153.01M$111.98M$210.78M
7 Day Performance0.29%7.10%5.50%2.82%
1 Month Performance-7.28%14.55%13.57%5.19%
1 Year Performance76.94%6.90%13.73%8.15%

Cytokinetics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ELAN
Elanco Animal Health
2.7385 of 5 stars
$16.47
+1.3%
$16.71
+1.5%
+42.1%$8.12B$4.37B-7.109,000Earnings Report
Analyst Report
Short Interest ↑
Analyst Revision
News Coverage
APLS
Apellis Pharmaceuticals
4.0842 of 5 stars
$69.35
-3.3%
$75.93
+9.5%
+6.4%$8.22B$75.42M-13.21767Earnings Report
Analyst Report
News Coverage
JAZZ
Jazz Pharmaceuticals
4.7745 of 5 stars
$132.26
-0.4%
$195.90
+48.1%
-6.4%$8.33B$3.66B150.302,800Positive News
CERE
Cerevel Therapeutics
0.6673 of 5 stars
$41.31
+0.6%
$39.64
-4.0%
+60.8%$7.49BN/A-16.52321Short Interest ↑
VKTX
Viking Therapeutics
3.9717 of 5 stars
$85.05
+121.0%
$50.88
-40.2%
+673.9%$8.55BN/A-92.4427Analyst Report
News Coverage
Gap Up
High Trading Volume
ITCI
Intra-Cellular Therapies
4.4749 of 5 stars
$72.90
+1.9%
$81.42
+11.7%
+50.1%$7.06B$464.37M-49.93561Earnings Report
Insider Selling
Short Interest ↓
Analyst Revision
ASND
Ascendis Pharma A/S
1.1045 of 5 stars
$155.34
-1.4%
$158.29
+1.9%
+39.0%$8.96B$288.08M-16.79879
IONS
Ionis Pharmaceuticals
3.5889 of 5 stars
$47.41
+2.8%
$53.23
+12.3%
+30.9%$6.91B$788M-18.52796Earnings Report
Analyst Report
Short Interest ↑
ROIV
Roivant Sciences
3.9451 of 5 stars
$11.80
+0.9%
$16.50
+39.8%
+46.8%$9.51B$61.28M2.27904Positive News
BPMC
Blueprint Medicines
0.8483 of 5 stars
$99.79
+5.0%
$85.43
-14.4%
+146.3%$6.11B$249.38M-11.94661Analyst Report
High Trading Volume

Related Companies and Tools

This page (NASDAQ:CYTK) was last updated on 2/28/2024 by MarketBeat.com Staff